The oxysterol receptors [liver X receptors (LXRa and LXRb)] regulate cholesterol and lipid biosynthesis and several studies link dysregulation of these metabolic pathways to aberrant cell growth. Here, we show that activation of LXR significantly reduced proliferation in several human breast cancer cells lines. LXR suppressed messenger RNA and/or protein expression of Skp2, cyclin A2, cyclin D1 and estrogen receptor (ER) a, whereas it increased the expression of p53 at the protein level and maintained the retinoblastoma protein in a hypophosphorylated active form. These changes may constitute part of the molecular mechanisms behind the antiproliferative effect of LXR. Furthermore, activation of LXR induced expression of key lipogenic genes including sterol regulatory element-binding protein 1c (SREBP1c), fatty acid synthase and stearoyl-coenzyme A desaturase 1, leading to increased triglyceride production in MCF7 cells. Small interfering RNA knockdown of SREBP1c, a master regulator of the lipid biosynthesis, did not abolish the antiproliferative effect of LXR in these cells. Combined these studies identify LXRs as both antiproliferative and lipogenic factors in breast cancer cells and indicate that the antiproliferative effect of LXRs is independent of lipid biosynthesis.
Introduction
The oxysterol receptors [liver X receptors (LXRa and LXRb)] are established sensors of intracellular cholesterol and lipid metabolism that become transcriptionally active upon binding of certain oxysterols. LXRs mediate their biological effects through transcriptional regulation of their target genes many of which are key regulatory genes involved in lipogenesis and cholesterol metabolism. These genes include sterol regulatory element-binding protein 1c (SREBP1c), stearoyl-coenzyme A desaturase 1 (SCD1), fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC) that increase fatty acid and triglyceride (TG) production (reviewed in ref. 1) . These transcriptional effects are reflected physiologically in vivo as LXRa À/À mice fed a high fat diet show significantly lower hepatic TG levels compared with wildtype mice (2) , and serum and hepatic TG levels are dramatically reduced in LXRab À/À mice (3). Reduced TGs are not found in LXRa À/À or LXRb À/À mice compared with wild-type C57BL/6 mice on a normal diet (4) .
A wide variety of cancers show increased lipogenesis and expression of lipogenic enzymes including SREBP1c, FAS and ACC (5) . Interestingly, recent work has identified LXRs as antiproliferative factors suppressing growth of both normal and cancer cells (6) . Activation of LXRs suppresses proliferation (7, 8) and the LXR agonist T0901317 acts as an androgen receptor antagonist in prostate cancer cells (9) . Moreover, LXR suppresses expression of 17b-hydroxysteroid dehydrogenase type 2 (10) , thereby interfering with steroid hormone production in these cells. In this study, we show that LXRs are antiproliferative factors in several human breast cancer cells.
Materials and methods

Cell culture
Human breast adenocarcinoma cell line, MCF7, was cultured in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA) containing 5.6 mM glucose, 1 mM sodium pyruvate, 4 mM L-glutamine, 25 mM N-2-hydroxyethylpiperazine-N#-2-ethanesulfonic acid and 2-10% fetal bovine serum (FBS, Saveen Werner, Malmö, Sweden). Human breast ductal carcinoma cell line, T47D, was cultured in F12:Dulbecco's modified Eagle's medium (1:1) (Invitrogen) containing 17.5 mM glucose, 0.5 mM sodium pyruvate, 2.5 mM L-glutamine, 13 mM N-2-hydroxyethylpiperazine-N#-2-ethanesulfonic acid and 5% FBS. Human estrogen receptor (ER)-negative breast cancer cell lines, SK-BR3 and MDA-MB-231, were grown in RPMI 1640 (Invitrogen) containing 11 mM glucose, 2 mM L-glutamine and 10% FBS. During starvation, the cells were maintained in Dulbecco's modified Eagle's medium without phenol red (Invitrogen) containing 5.6 mM glucose, 1 mM sodium pyruvate and 5% charcoal-stripped FBS. All cell culture media were supplemented with 100 U/ml penicillin and 100 lg/ml streptomycin (Invitrogen).
Proliferation assay
A total of 2 Â 10 5 cells were plated in six-well plates and treated as indicated for the respective experiments. At the end of the experiments, cells were incubated with 30 lM bromodeoxyuridine (BrdU) for 20-60 min followed by detachment using trypsin-EDTA solution (Invitrogen) and fixed in 75% ethanol. DNA was unwinded using 2 M HCl for 30 min and neutralized with 0.1 M sodium borate (Na 2 B 4 O 7 ). BrdU incorporation was detected with anti-BrdU antibody (Becton Dickinson, Franklin Lakes, NJ) followed by a fluorescein isothiocyanate-conjugated secondary antibody (Jackson Immunoresearch, West Grove, PA). DNA was counterstained with 10 lg/ml propidium iodide in phosphate-buffered saline for 30 min. Before treatment with ER agonist, estradiol (E 2 ; Sigma-Aldrich, St Louis, MO), MCF7 cells were synchronized for 24 h by serum deprivation. The cells were then initially incubated for 48 h with vehicle [dimethyl sulfoxide (DMSO)] or GW3965 LXR agonist before 24 h treatment with vehicle (ethanol) or increasing concentrations of E 2 . For ER antagonist treatment, ICI-182780 (ICI, Tocris Bioscience, Ellisville, MO) was used.
Intracellular TG measurements A total of 2 Â 10 6 MCF7 cells were plated in 10 cm dishes. After 16 h, the medium was replaced, cells were treated with vehicle or 10 lM GW3965 for 72 h and harvested. TGs were determined in 200 ll aliquots as described previously (11) . TG values were normalized to the protein concentration in each analyzed sample.
RNA interference
A total of 1 Â 10 4 and 3 Â 10 5 MCF7 cells were plated in 96-or 6-well plates for gene expression profiles and proliferation assays, respectively. Cells were grown to 30% confluence and transfected with 50 nM validated SREBP1 (Ambion/Applied Biosystems, Foster City, CA) or control (siLuc; Dharmacon/ Thermo Fisher Scientific, Waltham, MA) samll interfering RNA (siRNA) oligos using DharmaFECT 4 reagent (Dharmacon) according to the manufacturer's instructions. Medium was replaced 6 h after transfection, cells were treated with vehicle (DMSO) or GW3965 LXR agonist for a further 48 h and cells were harvested. To validate the knockdown efficacy, analysis of both messenger RNA (mRNA) and protein expression levels was performed on samples under the same conditions, see below.
Quantitative polymerase chain reaction Total RNA was isolated using the E.Z.N.A. Total RNA Kit I (Omega Bio-Tek, Norcross, GA). Five hundred nanograms RNA was reverse transcribed using the SuperScript II reverse transcriptase kit (Invitrogen). Quantitative polymerase chain reaction was performed using the SYBR Green technology using the Power SYBR mastermix (Applied Biosystems) and amplified in a 7500 fast real-time polymerase chain reaction system (Applied Biosystems). Primers were designed using Primer Express software; primer sequences are available on request. We calculated relative changes by the comparative C T method using 18S as the reference genes.
Abbreviations: BrdU, bromodeoxyuridine; DMSO, dimethyl sulfoxide; E 2 , estradiol; ER, estrogen receptor; FAS, fatty acid synthase; FBS, fetal bovine serum; LXR, liver X receptor; mRNA, messenger RNA; Rb, retinoblastoma; SCD1, stearoyl-coenzyme A desaturase 1; siRNA, small interfering RNA; SREBP1c, sterol regulatory element-binding protein 1c; TG, triglyceride.
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Western blot For protein expression levels in MCF7 cells, 5 Â 10 5 cells were plated in sixwell plates. Medium was replaced after 16 h and cells were treated with DMSO, GW3965 or T0901317 for 72 h. Cells were harvested directly in 1Â sodium dodecyl sulfate protein loading buffer and boiled for 5 min. The proteins were separated on 8-12.5% sodium dodecyl sulfate-polyacrylamide gels using standard procedures. The antibodies used were against ERa (F-10), Skp2 p45 (H-435), p53 (DO-1) (Santa Cruz Biotechnology, Santa Cruz, CA), SCD1 (CD.E10) (GeneTex, San Antonio, TX), p27 (Ambion), cyclin D1 (bcl-1 Ab-3) (Thermo Fisher Scientific, Fremont, CA) and b-actin (Sigma-Aldrich). Analysis of retinoblastoma (Rb) tumor suppressor protein phosphorylation was performed with Rb Antibody Sampler Kit (Cell Signaling Technology, Danvers, MA) according to the manufacturer's instructions. Analysis of siRNA-transfected samples was performed as described above. Additional antibody used was against SREBP1 (BD Biosciences). Ã P , 0.05, ÃÃ P , 0.01 and ÃÃÃ P , 0.001 using Student's t-test. Ã P , 0.05, ÃÃ P , 0.01 and ÃÃÃ P , 0.001 using Student's t-test.
LXR is antiproliferative in MCF7 cells
MDA-MB231 and SK-BR3 expressed both LXRa and LXRb (results not shown) and showed induced expression of known LXR target genes including ABCA1 and SREBP1c ( Figure 1A ) as well as ABCG1 and SCD1 (results not shown) upon activation of LXRs with the GW3965 LXRa-and LXRb-selective agonist. Hence, we conclude that LXRs are expressed in these cells and its transcriptional potential activated by an agonist. We analyzed the effect of LXRs on proliferation using BrdU pulses (BrdU stains proliferative cells in the S-phase of the cell cycle) and quantification of the cell population in the G 1 /G 0 phase of the cell cycle. We observed a dose-dependent decrease in BrdU incorporation and an increase in accumulation of cells in G 1 /G 0 phase using the T0901317 LXR agonist (a second LXRa and LXRb agonist) (supplementary Figure 1 is available at Carcinogenesis Online). Flow cytometry dot blots ( Figure 1B , upper panel) and histograms ( Figure 1B, middle panel) showed a clear decrease in number of BrdU-stained cells and an increased number of cells in the G 1 /G 0 phase upon activation of LXRs. The data are summarized in a bar diagram ( Figure 1B, lower panel) . This antiproliferative effect was more pronounced when using reduced (2%) serum in the cell culture medium and was equally significant using both GW3965 and T0901317 LXR agonists. The antiproliferative effect of LXR was also seen in another ERa-positive breast cancer cell line, T47D, using the GW3965 LXR agonist ( Figure 1C) . However, the antiproliferative effect was nearly abolished using two ERa-negative cell lines, MDA-MB231 and SK-BR3 ( Figure 1D ), suggesting that ERa might be an important mediator of the effect. To further investigate this, we performed two sets of experiments. Firstly, proliferation of MCF7 cells was boostered by an increasing amount of the ERa agonist E 2 ± GW3965. However, as outlined in Figure 2A , activation of LXRs decreased BrdU staining and induced G 1 /G 0 arrest indicating that LXRs dampen E 2 -induced proliferation. Secondly, cells were treated with ERa antagonist ICI to inhibit ERa-driven proliferation. We used a suboptimal ICI concentration (0.1 nM) in order not to shut off proliferation completely. The antiproliferative effect of LXRs was abolished under these inhibitory conditions of ERa ( Figure 2B ).
LXRs regulate expression of cell cycle genes and lipogenic genes in MCF7 cells
We performed mRNA and protein expression profiles in an effort to elucidate the detailed molecular mechanisms underlying the antiproliferative effect of LXRs. T0901317 and GW3965 dose dependently induced known LXR target genes ( Figure 3A, upper panel) . Interestingly, the mRNA induction of lipogenic target genes including SREBP1c, SCD1 and FAS peaked at low agonist concentration. In contrast, expression of genes involved in cell cycle progression such as SKP2, cyclinA2, cyclin D1 and ERa was suppressed by the same concentration of LXR agonist as those that repressed proliferation. These mRNA expression profiles were paralleled at the protein level for SCD1, ERa and Skp2 while the internal control b-actin remained unchanged ( Figure 3B and C). Skp2 ubiquitinates and degrades p27 and p21; however, we did not observe an increased expression of p27 and p21 ( Figure 3B and results not shown). p53 protein levels were induced by LXR ( Figure 3C ). To investigate if this reflects an active form of p53, we transiently transfected p53-responsive luciferase reporter vectors into MCF7 cells. Figure 3D shows that activation of LXRs significantly induced reporter activity using a gene regulatory region containing 13 repeats of a known p53 response element (G13). This was also seen with a reporter containing 100 bp of the Mdm2 gene regulatory region known to be responsive to p53 (pB-100). Furthermore, we analyzed the phosphorylation status of the Rb protein using phospho-specific Rb antibodies ( Figure 3E ). Activation of LXRs did not change the expression of total Rb protein but significantly reduced phosphorylation of Ser780 and Ser795, but not Ser807/811. Reduced phosphorylation at Ser780 and Ser795 is related to an active form of the Rb protein that binds E2F and inhibits cell cycle progression (12) . Taken together, we observe at the molecular level that LXRs are able to inhibit proliferation via several mechanisms.
The antiproliferative effect of LXRs is independent of their lipogenic activity The fact that increased expression of lipogenic enzymes has been linked to cancer progression and that we observed a large LXR-mediated effect on key lipogenic genes in the MCF7 cell line prompted us to ask if the antiproliferative effect of LXRs is dependent on lipogenesis. Activation of LXRs induced production of TGs ( Figure 4A ) in agreement with our observation that SREBP1c, the master regulator of lipid biosynthesis, as well as SCD1 and FAS are induced in MCF7 cells. Next, we knocked down SREBP1c in MCF7 cells using siRNA targeting SREBP1c and analyzed the proliferative effect of LXRs. siRNA targeting of SREBP1c reduced expression of SREBP1c ( Figure 4B ) as well as expression of SREBP1c target genes such as SCD1 and FAS. mRNA expression of SKP2 was also reduced, whereas no effect was observed on ABCA1, p53 or ERa. Knockdown of SREBP1c precursor was further confirmed at the protein level as well as the SREBP1c target gene SCD1 ( Figure 4C ), whereas the b-actin internal control was not changed. The antiproliferative effect of LXRs was not affected by knockdown of SREBP1c ( Figure 4D) ; however, in line with the reduced expression of SKP2, knockdown of SREBP1c reduced proliferation in MCF7 cells. These results confirm that lipid metabolism is involved in cell cycle regulatory events but that the antiproliferative effect of LXRs is independent of their role in lipogenesis.
Discussion
In addition to the reported antiproliferative effects of LXRs in human cancer cell lines, outlined in the Introduction, activation of LXRs also reduced proliferation and caused growth arrest in vascular smooth muscle cells (13) . In keratinocytes, LXRb induces epidermal differentiation and inhibits hyperproliferative epidermis in vivo (14) . Activation of LXRs with their endogenous agonist, 22(R)-hydroxycholesterol, inhibited proliferation of human teratocarcinoma precursor cells and induced these cells to differentiate into neuron-or astrocyte-like cells (15) . Recently, an indirect antiproliferative role of LXRs was documented where activation of LXR induced hepatic expression of the estrogen deactivation enzyme, estrogen sulfotransferase, which led to inhibition of breast cancer growth in a nude mouse model of tumorigenicity (16) . In this study, we provide evidence for a strong antiproliferative effect of LXRs in human breast cancer cell lines. Signaling lipids including fatty acids participate in control of cellular processes such as metabolism and cell proliferation. LXRa and LXRb are important sensors of cholesterol and lipid metabolism. We observed less proliferation of MCF7 cells when SREBP1c was knocked down, in support of earlier observations that SREBP1c is stabilized during mitosis, providing a link between lipid biosynthesis and cell growth (17) . Interestingly, LXRs might have a dual role in this respect. First, LXRs are antiproliferative in the breast cancer cells. Second, LXR-induced expression of lipogenic genes peaked at lower agonist concentration than needed for the antiproliferative effect of LXR. Hence, regulation of lipid production by LXRs seems to be mechanistically different from that of the antiproliferative effect of LXRs. Nevertheless, our results indicate that reduced proliferation by LXRs is independent of SREBP1c and lipogenesis.
Here, we show that a strong antiproliferative effect of LXRs is dependent on the estrogen-signaling pathway, as indicated by the fact that (i) the LXR effect was by far more pronounced in ERa-positive cell lines; (ii) activation of LXRs reduced estrogen-induced proliferation; (iii) the LXR effect was markedly reduced in the presence of the ICI ERa inhibitor and (iv) activation of LXRs reduced expression of ERa at the mRNA and protein levels. Furthermore, activation of LXRs reduced the mRNA and/or protein levels of Skp2, cyclin A2 and cyclin D1. LXRs induced expression of p53 at the protein level that was associated with the active form of p53 and the Rb protein was hypophosphorylated at Ser780/Ser795 associated with the transcriptionally repressive form of Rb. These observations strongly suggest that LXRs act upon several molecular targets regulating cell cycle that is in line with our observations that there is also a small, but significant, antiproliferative effect in ERa-negative cells.
Oxysterol receptors in general and LXRs in particular are wellsuited targets for drug development as they are transcription factors easily activated/deactivated by small compounds that can penetrate the cell membrane and modulate receptor activity in vivo. LXRs are interesting drug targets for pharmacological intervention of various metabolic disorders. The present and other recent reports establishing LXRs as regulators of cell growth indicate that LXR signaling may also be a potential target for anticancer drugs.
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